search
Back to results

Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial (KEEP PACE)

Primary Purpose

Critical Illness

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ketamine / Propofol Admixture
Etomidate
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Critical Illness focused on measuring Critical care, Emergent, Etomidate, Hemodynamics, Intensive care unit, Intubation, Ketamine-Propofol admixture

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years of age or older
  • Surgical or medical intensive care unity patients requiring endotracheal intubation
  • Consulting physician agrees to study plan and will follow drug randomization

Exclusion Criteria:

  • Known intracranial pathology
  • Known chronic opiate-dependence
  • Received continuous sedative infusion in the last 24 hours
  • Known severe psychiatric illness
  • Known egg allergies
  • Known contraindication to fentanyl, midazolam, ketamine, propofol or etomidate
  • Intubation in which standard practice is not to use sedation
  • No known documented weight or weight greater than 140 kg or less than 30 kg
  • Prior participation in the study
  • Of childbearing age (18-50) with no known negative pregnancy test on this admission.

Sites / Locations

  • Mayo Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Etomidate

Ketamine / Propofol Admixture

Arm Description

weight based dose of 0.15mg/kg

weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol

Outcomes

Primary Outcome Measures

Mean Arterial Pressure
Mean arterial pressure for the ketamine/propofol group at a 1:1 dose ratio compared to the etomidate group within the first 15 minutes post-administration in patients in need of urgent and/or emergent endotracheal intubation, as defined by any intubation within the intensive care unit excluding intubations for elective procedural events and codes.

Secondary Outcome Measures

Mortality
In-hospital/28 day mortality among patients in ketamine/propofol combination compared to in-hospital/28-day mortality in etomidate.
Vasopressor Use
The use of vasoactive medications to restore the blood pressure post-administration in the ketamine/propofol combination as compared to the etomidate group.
Number of Participants With Adrenal Insufficiency
Incidence of adrenal insufficiency between ketamine/propofol admixture and etomidate. Adrenal insuffiency was evaluated with co-syntropin stimulation test.
Mechanical Ventilation Free Days
comparison of mechanical ventilation free days between the two groups
Blood Product Transfusions
blood product transfusions [Red Blood Cells vs. non-Red Blood Cells] between the two groups
Intensive Care Unit Free Days
comparison of intensive care unit free days between the two groups
Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU
Comparison of number of participants who were positive for delirium using CAM-ICU between groups

Full Information

First Posted
March 31, 2014
Last Updated
May 28, 2020
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT02105415
Brief Title
Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial
Acronym
KEEP PACE
Official Title
Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
November 28, 2017 (Actual)
Study Completion Date
August 1, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The hypothesis of this study is that a Ketamine / Propofol mixture will produce more stable hemodynamics as compared to Etomidate during emergent intubations in the intensive care unit. Patients that require a breathing tube to be placed in the ICU will be randomized to receIve either a Ketamine / Propofol mixture or Etomidate for sedation in order to place the breathing tube.
Detailed Description
Endotracheal intubation is a procedure that may cause significant hemodynamic perturbations and can severely impact the outcome of the critically ill. To ensure a safe outcome during this particular procedure, there are many factors that the clinician is faced with. One decision that confronts the critical care physician involves the correct combination of medications with which to facilitate such a safe outcome. Given the reported hemodynamic stability, etomidate is a medication that is chosen by many providers in this particular situation. However, its association with a possible increase in mortality makes it less than ideal for a number of critical care physicians. In recent years, an admixture of propofol and ketamine has been studied that demonstrates hemodynamic stability based on the balancing of the hemodynamic effects of these two individual agents alone. This novel medication combination, sometimes referred to as "ketofol", may offer a valuable alternative to the critical care physician. Therefore, a randomized parallel-group clinical trial of adult critically ill patients admitted to a medical and/or surgical intensive care unit at Mayo Clinic Rochester who meet the criteria designated below for which urgent and/or emergent intubation is needed will receive one of two interventions based on stratified randomization. The "active" intervention arm will receive ketamine/propofol (ketofol) to facilitate endotracheal intubation. The comparison arm will receive etomidate. The primary outcome will focus on hemodynamic data recorded during the first 5 minutes post-administration with secondary outcomes looking at hemodynamic data at 10 and 15 minutes and addressing intensive care unit length of stay, mortality, adrenal function, and vasoactive medication use, among others.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness
Keywords
Critical care, Emergent, Etomidate, Hemodynamics, Intensive care unit, Intubation, Ketamine-Propofol admixture

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Etomidate
Arm Type
Active Comparator
Arm Description
weight based dose of 0.15mg/kg
Arm Title
Ketamine / Propofol Admixture
Arm Type
Experimental
Arm Description
weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol
Intervention Type
Drug
Intervention Name(s)
Ketamine / Propofol Admixture
Intervention Type
Drug
Intervention Name(s)
Etomidate
Primary Outcome Measure Information:
Title
Mean Arterial Pressure
Description
Mean arterial pressure for the ketamine/propofol group at a 1:1 dose ratio compared to the etomidate group within the first 15 minutes post-administration in patients in need of urgent and/or emergent endotracheal intubation, as defined by any intubation within the intensive care unit excluding intubations for elective procedural events and codes.
Time Frame
baseline and every 5 minutes up to 15 minutes minutes post study drug administration
Secondary Outcome Measure Information:
Title
Mortality
Description
In-hospital/28 day mortality among patients in ketamine/propofol combination compared to in-hospital/28-day mortality in etomidate.
Time Frame
Hospital Discharge or Day 28, whichever comes first
Title
Vasopressor Use
Description
The use of vasoactive medications to restore the blood pressure post-administration in the ketamine/propofol combination as compared to the etomidate group.
Time Frame
up to 24 hours post study drug administration
Title
Number of Participants With Adrenal Insufficiency
Description
Incidence of adrenal insufficiency between ketamine/propofol admixture and etomidate. Adrenal insuffiency was evaluated with co-syntropin stimulation test.
Time Frame
up to 24 hours post study drug administration
Title
Mechanical Ventilation Free Days
Description
comparison of mechanical ventilation free days between the two groups
Time Frame
hospital discharge or day 28, whichever comes first
Title
Blood Product Transfusions
Description
blood product transfusions [Red Blood Cells vs. non-Red Blood Cells] between the two groups
Time Frame
hospital discharge or day 28, whichever comes first
Title
Intensive Care Unit Free Days
Description
comparison of intensive care unit free days between the two groups
Time Frame
hospital discharge or day 28, whichever comes first
Title
Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU
Description
Comparison of number of participants who were positive for delirium using CAM-ICU between groups
Time Frame
up to 24 hours post study drug administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age or older Surgical or medical intensive care unity patients requiring endotracheal intubation Consulting physician agrees to study plan and will follow drug randomization Exclusion Criteria: Known intracranial pathology Known chronic opiate-dependence Received continuous sedative infusion in the last 24 hours Known severe psychiatric illness Known egg allergies Known contraindication to fentanyl, midazolam, ketamine, propofol or etomidate Intubation in which standard practice is not to use sedation No known documented weight or weight greater than 140 kg or less than 30 kg Prior participation in the study Of childbearing age (18-50) with no known negative pregnancy test on this admission.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nathan J Smischney, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
31335755
Citation
Smischney NJ, Nicholson WT, Brown DR, Gallo De Moraes A, Hoskote SS, Pickering B, Oeckler RA, Iyer VN, Gajic O, Schroeder DR, Bauer PR. Ketamine/propofol admixture vs etomidate for intubation in the critically ill: KEEP PACE Randomized clinical trial. J Trauma Acute Care Surg. 2019 Oct;87(4):883-891. doi: 10.1097/TA.0000000000002448.
Results Reference
derived
PubMed Identifier
25909406
Citation
Smischney NJ, Hoskote SS, Gallo de Moraes A, Racedo Africano CJ, Carrera PM, Tedja R, Pannu JK, Hassebroek EC, Reddy DR, Hinds RF, Thakur L. Ketamine/propofol admixture (ketofol) at induction in the critically ill against etomidate (KEEP PACE trial): study protocol for a randomized controlled trial. Trials. 2015 Apr 21;16:177. doi: 10.1186/s13063-015-0687-0.
Results Reference
derived

Learn more about this trial

Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial

We'll reach out to this number within 24 hrs